Overview
BioSerenity is a Paris-based medical technology company pioneering connected medical garments and AI-powered diagnostic tools for neurology and cardiology. Founded in 2014 as a spinout from Pitié-Salpêtrière Hospital (one of Europe’s leading neuroscience centers), the company develops wearable medical devices embedded in everyday garments — shirts, pajamas, caps — that continuously monitor patients’ neurological and cardiac signals outside the hospital environment. This “hospital at home” model addresses a fundamental challenge in neurological disease management: the episodic nature of conditions like epilepsy means that traditional clinical EEG monitoring (brief sessions in a hospital EEG lab) frequently misses events that occur during daily life.
BioSerenity’s flagship product is the SPEAC System for seizure documentation — a connected EEG cap that enables patients to record and transmit brain activity data to clinicians remotely. The company has expanded into cardiac monitoring with connected garments for arrhythmia detection, and into sleep medicine with home-based polysomnography solutions. The commercial model combines device sales with recurring clinical data management services — a medical SaaS approach that generates higher lifetime customer value than standalone device sales.
France 2030 Funding & Projects
BioSerenity participates in France 2030’s health innovation axis through multiple funding mechanisms. The company has received Bpifrance deeptech innovation funding and participated in France 2030’s “Health Innovation” programs that target medical device innovation combining connected health, AI diagnostics, and remote patient monitoring. France’s national health insurance (Assurance Maladie) reimbursement pathway for connected health devices — which BioSerenity has navigated for its epilepsy monitoring system — is a France 2030-adjacent policy development that creates revenue certainty for medical device companies that successfully achieve reimbursement.
The company has collaborated with INSERM (the French National Institute of Health and Medical Research) — a France 2030-designated research institution — for clinical validation studies of its AI-powered seizure detection algorithms. These academic-industrial collaborations, facilitated by France 2030’s health research program, accelerate regulatory approval processes by generating the clinical evidence required by ANSM (France’s medical device regulator) and the CE marking process.
Strategic Position
BioSerenity operates in the connected health and wearable medical device market — a segment projected to reach $60 billion globally by 2027 — competing with established medical device companies (Natus Medical, Compumedics) in clinical neurophysiology equipment and with digital health companies (iRhythm for cardiac monitoring, Apple Health for consumer wellness monitoring). The company’s competitive differentiation is the clinical-grade data quality of its garment-integrated sensors combined with the AI interpretation layer that converts raw physiological data into actionable clinical information.
The pivot from hospital-based to home-based neurodiagnostics is structurally driven by healthcare economics: hospital neurophysiology departments are expensive, overburdened, and geographically concentrated. Home-based monitoring can dramatically expand the number of patients who can access neurophysiological investigation, improving diagnostic rates for epilepsy (historically underdiagnosed), cardiac arrhythmias (frequently missed by brief Holter monitors), and sleep disorders.
Key Technology & Innovation
BioSerenity’s core technical capability is the seamless integration of medical-grade electrodes and electronics into textile garments without compromising either wearability or signal quality. Dry electrodes (not requiring conductive gel) suitable for non-clinical home use must achieve acceptable signal quality for clinical interpretation — a materials science and signal processing challenge that the company has addressed through proprietary electrode design and artifact-rejection algorithms.
The AI interpretation layer — trained on clinical datasets from BioSerenity’s hospital partner networks — classifies EEG and ECG patterns to identify clinically significant events, reducing clinician interpretation time while maintaining sensitivity for the events that matter. These AI models, developed in collaboration with French neurological and cardiac clinical research centers, represent IP that is difficult for pure technology companies to replicate without access to equivalent clinical datasets.
Leadership
Pierre-Yves Frouin serves as CEO, having guided BioSerenity’s transition from a hospital spinout to a commercial medical device company with international ambitions. The founding connection to Pitié-Salpêtrière Hospital provides ongoing clinical collaboration that keeps BioSerenity’s product development grounded in clinical reality — a structural advantage over pure technology companies developing medical devices without deep clinical partnerships.
Competitive Landscape
In clinical EEG monitoring, BioSerenity competes with Natus Medical (now Integra LifeSciences), Nihon Kohden (Japan), and Compumedics (Australia). In the home monitoring segment, it competes with iRhythm (cardiac), Nuvectra, and emerging connected health platforms from consumer electronics companies including Apple and Samsung that are integrating clinical capabilities into consumer devices. The clinical regulatory approval of BioSerenity’s devices (CE marked, FDA registered) provides differentiation from consumer wellness devices that cannot be used for clinical decision-making.
Investor Perspective
BioSerenity is a growth-stage medical technology company with clinical validation and commercial traction in neurology monitoring. The company’s path to larger scale depends on reimbursement expansion — securing national health insurance coverage across European markets for its connected monitoring services. France’s health tech reimbursement framework, under which BioSerenity has achieved initial coverage, is the template for European expansion.
France 2030’s health innovation programs provide both funding support and regulatory relationship facilitation that accelerate BioSerenity’s market access. For investors, the company represents the intersection of France’s medical research excellence (Pitié-Salpêtrière legacy) and commercial medical device development — a combination with genuine global market potential if the reimbursement pathway scales.